Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael B Atkins

Showing results (141-150 of 338) with videos related to

Pageof 34
Sort By:
Molecular Cancer Therapeutics|August 12, 2010
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signalingRupal S Bhatt, Xiaoen Wang, Liang Zhang, et al.
Clinical Genitourinary Cancer|September 12, 2022
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney CancerZeynep B Zengin, Sumanta K Pal, David F McDermott, et al.
Cancer|February 2, 2010
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanomaRupal S Bhatt, Jaime Merchan, Robert Parker, et al.
The Lancet. Oncology|December 8, 2019
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label studyBrian I Rini, Sumanta K Pal, Bernard J Escudier, et al.
Journal of Translational Medicine|December 23, 2011
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinomaXiaoen Wang, Liang Zhang, S Nahum Goldberg, et al.
Cancers|September 23, 2022
Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. <i>Cancers</i> 2021, <i>13</i>, 6109Dongyu Zhang, Neil J Shah, Michael Cook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2015
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)Keith T Flaherty, Judith B Manola, Michael Pins, et al.
Cancer Research|May 4, 2021
Targeting DDX3X Triggers Antitumor Immunity via a dsRNA-Mediated Tumor-Intrinsic Type I Interferon ResponseHyeongjwa Choi, Juntae Kwon, Min Soon Cho, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 2, 2007
Report on the ISBTC mini-symposium on biologic effects of targeted therapeuticsMichael B Atkins, David Carbone, George Coukos, et al.
Investigational New Drugs|January 28, 2021
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapyToni K Choueiri, Michael B Atkins, Tracy L Rose, et al.
Pageof 34

Showing results (141-150 of 338) with videos related to

Sort By:
Pageof 34
Molecular Cancer Therapeutics|August 12, 2010
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signalingRupal S Bhatt, Xiaoen Wang, Liang Zhang, et al.
Clinical Genitourinary Cancer|September 12, 2022
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney CancerZeynep B Zengin, Sumanta K Pal, David F McDermott, et al.
Cancer|February 2, 2010
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanomaRupal S Bhatt, Jaime Merchan, Robert Parker, et al.
The Lancet. Oncology|December 8, 2019
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label studyBrian I Rini, Sumanta K Pal, Bernard J Escudier, et al.
Journal of Translational Medicine|December 23, 2011
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinomaXiaoen Wang, Liang Zhang, S Nahum Goldberg, et al.
Cancers|September 23, 2022
Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. <i>Cancers</i> 2021, <i>13</i>, 6109Dongyu Zhang, Neil J Shah, Michael Cook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2015
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)Keith T Flaherty, Judith B Manola, Michael Pins, et al.
Cancer Research|May 4, 2021
Targeting DDX3X Triggers Antitumor Immunity via a dsRNA-Mediated Tumor-Intrinsic Type I Interferon ResponseHyeongjwa Choi, Juntae Kwon, Min Soon Cho, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 2, 2007
Report on the ISBTC mini-symposium on biologic effects of targeted therapeuticsMichael B Atkins, David Carbone, George Coukos, et al.
Investigational New Drugs|January 28, 2021
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapyToni K Choueiri, Michael B Atkins, Tracy L Rose, et al.
Pageof 34